Skip to content

SPERO THERAPEUTICS, INC.

SPRO

CIK 0001701108

← back to feed
Revenue (TTM)
$12K
+3,292.5% YoY Q1 May 2026
Net Income (TTM)
−$30.15M
+112.5% YoY Q1 May 2026
EPS Diluted (TTM)
−$0.54
+111.8% YoY Q1 May 2026
Gross Margin
—
Q1 May 2026
Operating Margin
-271,908.3%
Q1 May 2026
Net Margin
-251,258.3%
Q1 May 2026
Free Cash Flow (TTM)
$4.79M
Q1 May 2026
Cash
$56.13M
Q1 May 2026
Total Debt
—
Q1 May 2026
Shares Outstanding
57.9M sh
Q1 May 2026

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings